GlassScriptPhysician profile
Benjamin R Boerner
NPI 1568089043
$7,451.02
in general payments reported to CMS, 2019-2025
22 companies · $2,326 in 2025
The $2,326 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $1,670 · 2023: $1,217 · 2024: $1,351 · 2025: $2,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,731 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,731.10 |
| Education | $162.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,982.67 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,097.08 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $824.66 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $641.54 | 2021-2025 | Dupixent |
| Csl Behring | $498.81 | 2021-2025 | Hizentra, Kcentra |
| Optinose US, INC. | $492.47 | 2021-2025 | |
| Kaleo, INC. | $378.39 | 2021-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $352.41 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $235.93 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $162.75 | 2022-2023 | |
| Amgen INC. | $154.72 | 2021-2025 | Tezspire |
| Covis Pharma Gmbh | $105.34 | 2021-2022 | |
| Genentech USA, INC. | $99.89 | 2023-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $96.28 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $82.04 | 2022-2024 | Ryaltris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $72.26 | 2021-2022 | |
| Grifols USA, LLC | $60.43 | 2025 | Xembify |
| Uswm, LLC | $35.85 | 2021 | |
| Alk-Abello, INC | $23.95 | 2022 | |
| Lilly USA, LLC | $19.00 | 2025 | Ebglyss |
| Biocryst US Sales Co., LLC | $17.46 | 2024 | Orladeyo |
| Octapharma USA, INC. | $17.09 | 2025 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Boerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.